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1. Introduction 
End stage renal disease (ESRD) affects over 400,000 Americans, and over 8 million have 
chronic renal insufficiency [1]. Chronic renal insufficiency (CRI) describes a continuum of 
impaired renal function based on several parameters including glomerular filtration rate 
and serum creatinine. As renal function deteriorates, the risk of all-cause mortality increases 
[1]. The most prevalent form of renal replacement therapy is hemodialysis (HD), with over 
75% of ESRD patients being treated with this modality [2, 3]. Patients requiring chronic HD 
have been noted to experience an increase in cardiovascular morbidity and mortality [4]. In 
fact, between 10-20% of patients who require HD die each year and approximately 45% of 
these deaths are attributable to cardiovascular causes [2, 3]. Hemodialysis itself is associated 
with substantial morbidity, including complications related to vascular access and those 
inherent to the HD procedure itself.  
One of the most common complications of hemodialysis is intradialytic hypotension (IDH), 
which occurs in approximately 25% of HD sessions [5]. There are several therapeutic options 
available for the treatment of IDH. However, “resistant” forms of IDH do occur and a 
multimodality approach is usually necessary in such cases. The aim of this chapter is to 
discuss IDH and outline existing clinical approaches to IDH. Specifically, we will focus on 
the use of methylene blue (MB) in the treatment of IDH. Methylene blue, a nitric oxide 
pathway mediator, has shown promise in prevention or treatment of IDH in difficult-to-
treat cases [6, 7].   
2. Overview of intradialytic hypotension 
IDH is seen in approximately 20-30% of hemodialysis sessions and is an independent risk 
factor for mortality [8]. During a typical HD session, an ultrafiltrate volume of 5 liters or 
greater may be removed with a concomitant 10-20% reduction in plasma volume [9, 10]. 
Intradialytic hypotension is likely multifactorial, and the inability of the cardiovascular 
system to adequately respond to the reduction in circulating plasma volume is among the 
leading factors.  
Most patients are able to compensate for the ultrafiltration fluid losses by “mobilizing” fluid 
from extravascular/interstitial space, and tissue hydration state has a strong influence on 
changes in plasma volume during fluid removal and subsequent repletion [11]. In cases 
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where IDH occurs, available strategies include a combination of vasopressor administration, 
intravascular volume expansion with intravenous colloid or crystalloid solutions, positional 
patient changes, and discontinuation of ultrafiltration [12]. Detailed discussion of the 
underlying physiology and therapies available to treat IDH will now follow. 
2.1 Physiology of intradialytic hypotension 
Intradialytic hypotension can have very serious sequelae, up to and including the 
development of life-threatening end-organ (i.e., cardiac, cerebral) hypoperfusion [12]. 
Factors contributory to IDH can be broadly divided into those related to the HD procedure 
and those related to underlying patient condition(s) [12]. Patient related factors, the focus of 
this chapter, can be further divided into cardiac (i.e., left ventricular hypertrophy, chronic 
volume overload, anemia (acute or chronic), diastolic and systolic dysfunction, cardiac 
arrhythmias, ischemic myocardial syndromes) and vascular (i.e., vasoplegia or impaired 
maintenance of appropriate vascular tone/systemic vascular resistance) [7, 12]. 
Hemodialysis related factors include the ultrafiltration rate, possible intra-procedural blood 
loss, and dialysate temperature profile [12, 13]. 
We will focus on the vascular-related aspects if IDH, concentrating on the vasoplegia 
associated with the HD procedure. The amount of fluid available in the interstitial space for 
“vascular refilling” is the one of the primary determinants of IDH. In the presence of excess 
fluid in the interstitial space, the patient is theoretically more likely to tolerate higher 
volumes of ultrafiltrate removal [11]. Conversely, patients with relatively smaller amounts 
of volume in the interstitial space are more susceptible to even small amounts of volume 
removal. Therefore the determination of the patient’s true dry weight is important to 
planning the amount of ultrafilatrate removal [14, 15]. It is important to remember that fluid 
shifts from the interstitial space to the intravascular space constitute a dynamic process and 
exhibit anatomic variations. For example, intravascular refilling is more vigorous in lower 
extremities because of the relative excess of extracellular fluid [16]. 
During ultrafiltration, the body’s initial response to volume reduction involves sympathetic 
mediated vasoconstriction [17]. This vasoconstriction shifts blood flow away from dermal 
circulation and reduces heat loss. However, this response may not always be sufficient, 
either due to impaired sympathetic response itself or excessive production of endogenous 
vasodilators [18]. Chromogranin A levels, which are co-released with catecholamines, are 
decreased significantly in the post-HD plasma of patients with IDH compared to patients 
with stable blood pressures [19]. In addition, it has been suggested that patients with 
significant uremia have autonomic dysfunction that may be due to chronic hyperkalemic 
depolarization [20]. 
Endothelial cells and vascular myocytes release adenosine, which also has been implicated 
in the development of IDH [21]. It is hypothesized that during dialysis there are local areas 
of tissue ischemia that release adenosine in response.  Antagonism of the A1 and A2 
adenosine receptors in patients with frequent IDH has been shown to reduce the incidence 
modestly [21]. Also, peripheral blood mononuclear cells show greater expression of A2A 
receptors in IDH-prone patients [22]. 
Patients undergoing HD tend to experience a net increase in body temperature [23, 24]. Core 
temperature continues to increase throughout the dialysis procedure and may be associated 
with impaired sympathetic response before the development of IDH [25]. Isothermic HD 
may improve patient hemodynamics and may help prevent IDH [24]. It is important to note 
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that the protective hemodynamic effects of cool dialysate may be most pronounced among 
patients with lower baseline (i.e., pre-HD) body temperatures [26]. 
Additional aspects of vasoplegia associated with HD in the context of nitric oxide (NO) 
pathways will be discussed in subsequent sections, along with the role of methylene blue 
(MB) as a potential therapeutic agent in this setting.   
2.2 Determination of dry weight and intravascular volume 
The dry weight of a given patient can be difficult to determine and can fluctuate depending 
on any concurrent acute and chronic illnesses [14]. Several methods of estimating dry 
weight exist and will be discussed in this section. Commonly used techniques are based on 
intravascular pressure measurements, bioimpedance determination, arterial waveform 
analysis, and various sonographic techniques [27-29]. Specific methods include blood 
volume monitoring with ultrafiltration pulses, central venous and other invasive vascular 
pressure measurements, ultrasound measurements of the inferior vena cava (diameter 
and/or collapsibility) or direct bioimpedance measurements (whole-body, segmental, calf) 
[27-29]. Of note, the use of invasive blood volume monitoring devices has been associated 
with greater nonvascular and vascular access related complications and mortality [30]. 
Recent developments in the area of intravascular monitoring and estimation of dry weight 
and intravascular volume favor the use of minimally invasive or non-invasive modalities 
such as ultrasonography [31]. Techniques such as the pulmonary artery catheter are 
becoming less popular.   
2.3 The role of nitric oxide in intradialytic hypotension 
Analyses of plasma from patients identified to be at high risk of IDH suggest that this group 
may have chronic elevations in plasma nitrites as well as significantly elevated nitrite 
production [32]. Hemodialysis itself is associated with increased  nitric oxide (NO) 
production [33]. When blood is exposed to hemodialysis membranes, endothelial cells show 
enhanced expression of inducible nitric oxide synthase (iNOS) mRNA in murine models 
[34]. In addition, uremic platelets produce increased amounts of NO [35]. It is speculated 
that cytokines, including IL-1┚ and TNF┙, released during HD by activated mononuclear 
cells cause activation of NOS. Interestingly, significant increases in NO production are noted 
in patients who experienced a hypotensive episode during HD when compared to those that 
did not experience hypotension, suggesting a causal relationship [6]. However, the exact 
nature of this relationship remains to be elucidated. 
NO is produced by two types of NO synthase (NOS) [7].  One exists in the endothelium and 
is constitutively active (eNOS). The other type is the inducible (iNOS) and exists in various 
tissues and cell types. Upregulation of iNOS results in increased NO production and 
generation of cGMP [7]. This can have profound effects on both the vasculature and 
myocardium.   
In end stage renal disease, not only is there in increase in baseline NO production, there is 
also an increase in inhibitors of NO, namely asymmetric dimethylarginine (ADMA) [36]. It 
turns out these inhibitors are dialyzable, which suggests that disturbances within the 
baseline interplay between specific activators and inhibitors during HD may contribute to 
hemodynamic instability [36, 37]. Direct serum measurements during HD confirm higher 
nitrate generation, which combined with a decrease in inhibitory factors may lead to IDH.  
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In addition to the vasodilatory effects of NO, hypotension may also result from NO’s 
negative inotropic properties [38]. Cholinergic agonists are known to elevate cGMP levels in 
cardiac myocytes and cGMP analogs may also produce profound negative chronotropic 
effects [39]. Exposure of cardiac myocytes to carbachol, a cholinergic agonist, results in 
suppressed contractility and chronotropy as well as profoundly increased levels of cGMP. 
This effect can be ameliorated by co-administration with methylene blue (MB) which 
suggests that NO dependent pathways may be involved [39]. Schematic representation of 
MB mechanism of action as well as pertinent metabolic pathways can be seen in Figure 1. 
 
 
Fig. 1. Schematic representation of NO/cGMP-dependent pathways. Note the endothelial 
(eNOS) and inducible (iNOS) isoforms of the nitric oxide synthase (NOS) and their 
associated functional steps. Methylene blue inhibits (white arrow on right) the action of 
soluble guanylyl cyclase (sGC) and thus prevents vasodilation. Adapted from Bosoy et al 
[65]. 
2.4 Treatment for intradialytic hypotension 
Evidence shows that episodes of intra- and post-dialytic hypotension are associated with 
increased morbidity and mortality [8]. This makes treatment and prevention of IDH an 
important part of both short- and long-term HD strategy. Several approaches to this 
problem exist and will be discussed in this section. 
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At the core of IDH is uncompensated response to reduction in circulating blood volume 
[40]. The patient may exhibit a blunted response to this reduction or the reduction may be 
too large to mount an effective response. Active monitoring of the dialysis patient’s blood 
volume can provide real-time data to the clinician concerning the patient’s volume status. 
Monitoring usually includes hematocrit, total protein and hemoglobin measurements, 
which cumulatively provide an estimate of total blood volume [41]. While the physiologic 
response to blood volume reduction varies considerably between patients, blood volume 
monitoring allows the clinician to tailor the treatment so the maximal tolerated blood 
volume changes are not exceeded. Clinical evidence shows that based on blood volume 
monitoring physicians are able to identify this maximum tolerated blood volume change in 
approximately 70% of patients, and the majority of hypotensive episodes occurred when 
this value is exceeded [42]. However, in almost 30% of patients such value could not be 
determined, suggesting that blood volume monitoring alone may not be sufficient for 
predicting risk of IDH in all patients. Ultrafiltration rate is also a very important 
determinant in the incidence of IDH. Altering the ultrafiltration rate to achieve a 
predetermined blood volume profile can reduce the incidence of IDH [43]. 
It has also been shown that limiting the reduction in plasma osmolarity during hemodialysis 
by altering the dialysate sodium concentration can enhance hemodynamic stability. In this 
paradigm, maintaining higher dialysate sodium concentration facilitates the maintenance of 
adequate intravascular blood volume [44]. The disadvantage to this method is that the 
higher sodium concentrations increase the amount of sodium available for exchange and 
may actually increase weight gain and precipitate hypertensive episodes. 
As discussed earlier, HD is associated with an increase in core body temperature and 
concomitant propensity for IDH. Preventing increases in core body temperature allows for a 
more stable blood pressure throughout the dialysis process [23]. Low temperature diasylate 
settings (approximately 37-38°C) significantly decrease the severity and frequency of 
symptomatic IDH [13]. In addition, the low temperature improves capacitance and 
resistance of peripheral blood vessels and may result in improved cardiac contractility [45]. 
The use of thermal neutral dialysis reduces the frequency of IDH events by approximately 
one-fourth. 
Several pharmacologic interventions also exist for the treatment of IDH. Midodrine is a 
prodrug that when metabolized acts as an alpha-1-receptor agonist. It can provide modest 
increases in both peripheral vascular resistance and cardiac output [46].  It is a well-tolerated 
medication with the most common side effects being piloerection, scalp itching/burning 
and nausea. Caution should be taken when administering midrodrine concurrently with 
negative chronotropic agents including ┚-blockers, digoxin and calcium channel blockers. 
Treatment regimens incorporating midodrine on the days of HD result in significant 
reductions in both intra- and post-dialytic hypotension [47].  
3. Overview of methylene blue characteristics 
Despite different therapeutic approaches to IDH, a significant proportion of patients 
undergoing dialysis continue to experience HD-related hypotension. In a quest for 
effective therapy for IDH, methylene blue (MB) has been evaluated as a potential adjunct 
in the setting of refractory hypotension. Methylene blue, a “natural pressor”, is an 
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aromatic chemical compound used in analytical chemistry, biology and medicine. It is a 
soluble compound that can be administered intravenously or orally/enterally. It functions 
by inhibiting guanylyl cyclase in vascular smooth muscle, and decreases the levels of 
cGMP [7, 48-51]. Methylene blue also scavenges nitric oxide and inhibits nitric oxide 
synthesis [7, 50]. 
3.1 Pharmacology of methylene blue  
Methylene blue is available in both an intravenous and oral form. Both forms undergo 
primarily urinary excretion with a half-life of approximately 4-5 hours [52]. Small amounts 
of MB are excreted in bile and feces as well [53].  Distribution appears to differ substantially 
between the two enteral and intravenous forms. Intravenous administration results in 
significantly higher concentrations within the blood and brain 1 hour after infusion when 
compared to the oral route. Bioavailability from oral administration ranges from 53-97% 
[54]. Oral administration results in much higher concentrations within the bowel wall and 
liver, with <3% of the administered MB remaining within the intestinal lumen after 
ingestion. Once in the blood, MB readily enters erythrocytes where it is reduced to 
leucomethylene blue at low concentrations. In high concentrations it can act as an oxidizing 
agent, potentially leading to hemolysis, methemoglobinemia and hyperbilirubinemia [53].  
Most side effects of MB appear to be dose-dependent and do not occur with doses below 2 
mg/kg [55]. Methylene blue can turn urine greenish-blue, and while this may be alarming to 
patients, it usually resolves within a few days of discontinuing MB. In addition, mild skin 
discoloration is common, but is self-limiting and treatable with administration of dilute 
hypochlorite solution [56]. Other side effects may include abdominal pain, nausea, 
vomiting, headaches, fever, confusion and diaphoresis [54].  Subcutaneous and intradermal 
injections should be avoided because they have been associated with necrosis and abscess 
formation [57]. Encephalopathy has been noted in one series that included five patients that 
received preoperative intravenous MB (3-5 mg/kg in 500 mL saline) for parathyroid 
adenoma localization.  All five cases of encephalopathy occurred in female patients taking 
serotonin-metabolism modifying agents [58].   
In the neonatal and pediatric populations, enteral MB administration of >2 mg/kg has been 
associated with severe methemoglobinemia, hemolytic anemia, Heinz body anemia, and 
hyperbilirubinemia [53]. Anemia following MB administration typically manifests within 24 
hours, peaks at 4-5 days and can persist for up to 12 days [59]. Futhermore, photosensitive 
epithelial desquamation after MB administration has been reported among infants 
undergoing phototherapy. This may be due to lysosomal membrane breakdown after 
interacting with light in the presence of photosensitizing MB [60].  Practitioners caring for 
patients receiving MB infusions have to be aware of falsely depressed oxygen saturation 
readings due to methylene blue interfering with the pulse oximeter’s light emission [61].   
3.2 The use of methylene blue in hypotensive patients 
Because of its ability to lower plasma levels of the endogenous vasodilator NO, methylene 
blue has been investigated in the clinical setting of difficult-to-treat hypotension. 
Investigational studies of MB in various hypotensive settings have been carried out, with 
some of the most compelling evidence coming from the areas of cardiac surgery, trauma, 
renal failure, and other forms of distributive shock.  
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Animal models of acute shock have been developed that facilitate objective testing of the 
role of MB in various forms of shock. Refractory hemorrhagic shock is seen most commonly 
in trauma patients and carries a high morbidity and mortality.  In canine models, untreated 
animals usually die within 30 minutes of onset of refractory hemorrhagic shock. When 
treated with an initial bolus of MB and volume resuscitation the mortality was 0% at 120 
minutes, compared to 75% for animals treated with volume resuscitation alone [62]. 
Animals treated with MB and volume resuscitation maintained significantly higher mean 
arterial pressures, increased cardiac output, better tissue perfusion, and increased oxygen 
delivery. Furthermore, MB administration has been associated with significant neurologic 
and myocardial protective effects during cardiopulmonary resuscitation. This is thought to 
be due to the effect of MB contributing to improved coronary perfusion pressure and cardiac 
index, as well as reduced cerebral perioxidation and inflammation [63].  
Hepatic failure may also be complicated by vasoplegia and hypotension. Hepatic failure is 
commonly associated with increased plasma concentrations of endotoxin in addition to 
other endogenous vasodilators. Moreover, up to 40% of patients with cirrhosis develop 
hepatorenal syndrome within 5 years of initial diagnosis [64]. Published case reports 
describe the use of MB in refractory hypotension associated with hepatorenal syndrome, 
where vasoplegic patients with refractory hypotension were able to become vasopressor free 
within 5 days of intiation of MB therapy, suggesting a role of increased NO activity in the 
pathogensis of hepatorenal syndrome-associated vasoplegia [65]. See Figure 2 for a clinical 
vignette demonstrating MB use in the setting of difficult-to-treat vasoplegia. For additional 
information regarding clinical uses of MB for hypotension in various clinical settings the 
reader is referred to Table 1. 
 
 
Fig. 2. Hemodynamic profile and vasopressor requirements of a middle-aged vasoplegic 
male patient after methylene blue (MB) administration. The patient experienced profound 
hypotension refractory to conventional management on day #2 following repair of type A 
aortic dissection. After the patient became essentially unresponsive to escalating 
vasopressor support, he received an intravenous injection of 2 mg/kg MB over 30 minutes 
(A and B, MB administration timing shaded in blue).  A) Blood pressure response to MB 
injection showing increase in both systolic and diastolic blood pressures. B) Vasopressor 
doses immediately prior, during, and after MB infusion. All vasopressors were weaned 
completely within 9 hours of MB administration. Legend: MB – methylene blue; Infusion 
rates – Vasopressin units/min; Epinephrine – mcg/kg/minute; Norepinephrine – 
mcg/kg/minute; Blood pressure listed in mmHg. 
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Author (ref, 
year) 
Clinical Setting Major results/findings 
Peer 
(6, 2001) 
Investigational study of MB 
administration in HD patients. (n=41, 
18 HD patients with hypotension, 18 
HD patients without hypotension, and 
5 healthy controls).  
MB was given as a bolus (1mg/kg) 
followed by an infusion (0.1 mg/kg) 
for 210 minutes until the end of HD 
session. On non-dialsysis days, only 
the bolus dose was given. 
In hypotension-prone patients, MB prevented 
the hypotension during dialysis and increased 
both systolic and diastolic blood pressure on 
non-dialysis days. 
In normotensive patients, MB increased blood 
pressure during the first hour of dialysis and 
during the first 90 minutes on non-dialysis days. 
The blood pressure in healthy controls 
remained unchanged.  
Preiser 
(67, 1995) 
Prospective medical-surgical ICU 
study involving patients with 
hypotension refractory to vasopressor 
therapy (n = 14). 
MB was given as a bolus (2 mg/kg) 
over 15 minutes. Additional dose was 
needed in 6 patients due to transient 
response to the initial bolus.  
MB administration was associated with 
increased mean arterial pressure and increas
systemic vascular resistance. A decrease in 
serum lactate following MB administration was
noted. 
 
Daemen-
Gubbels  
(68, 1995) 
Non-randomized clinical trial 
involving MB administration in the 
setting of sepsis. The trial involved 
consecutive patients with a pulmonary 
catheter in place (n = 9). 
MB was administered as an 
intravenous bolus (2 mg/kg). 
MB administration resulted in increased mean 
arterial pressure and oxygen uptake as well as
decrease in arterial complaiance.  
MB use was also associated with increased 
myocardial function and oxygen delivery. 
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Bosoy 
(65, 2008) 
Report describing MB use in 
vasoplegic patients with 
simulataneous hepatic and renal 
failure.  
One patient received MB bolus (1 
mg/kg) followed by another dose of 
0.5 mg/kg at 12 hours. Another 
patient received MB infusion of 1 
mg/kg, followed by an enteral-based 
MB regimen (1 mg/kg every 12 
hours).  
Both patients experienced significant 
hemodynamic improvement following MB 
administration.  
The first patient was successfully weaned off 
dual vasopressin-norepinephrine regimen. 
The second patient was able to leave the 
hospital and receive palliative care at home due 
to his ability to be vasopressor-free utilizing 
enteral (oral) methylene blue regimen. 
Jaskille  
(69, 2008) 
Case series of patients with severe 
burns (80-95% TBSA, n=2) and 
persistent hypotension despite 
simultaneous vasopressin and 
norepinephrine.  
Patient received single intravenous 
infusion (2mg/kg) of MB.  
Response to MB noted within 30 minutes. 
Significant reductions in pressor requirements, 
including complete resolution of vasoplegia 
within 2 hours in 1 patient.  
Del Duca  
(70, 2009) 
Case series of patients with 
intraoperative anaphylaxis during 
cardiac surgery. One case was a 
reaction to protamine, the other was a 
reaction to aprotinin.  
The patients were treated with 
intravenous MB (2mg/kg). 
Both patients had prompt resolution of 
hypotension and did not require additional M
doses. There were no adverse effects. 
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3.3 The use of methylene blue in hemodialysis and intradialyitc hypotension 
The use of MB may reduce the incidence of IDH in patients who are prone to this 
hemodynamic disorder [6]. Initial studies utilized a pre-HD bolus of MB and noticed lower 
incidence of intra- and post-dialytic hypotensive episodes. When given continuously to 
hypotension prone patients during HD, episodes of IDH were significantly reduced. Of 
interest, MB administration to normal controls did not cause appreciable changes in blood 
pressure, which corroborates the role of nitrate generation during HD as contributory to 
IDH. 
As discussed earlier, there is usually a reduction in circulating plasma nitrates during HD 
procedure [66]. However, following the procedure certain patients appear more prone to the 
development of circulating nitrate increases. Among patients who are more prone to 
develop IDH, a significant increase in nitrate production was noted on post-dialysis day 1 
compared to dialysis patients who are not prone to hypotension (1.21 +/- 0.13 µmol/min 
versus 0.61 +/- 0.11 µmol/min) [6]. In addition, when patients with propensity for IDH 
were treated with MB during the procedure, their 24-hour plasma nitrate production 
decreased significantly compared to untreated individuals, further supportiny the role of 
NO production and cGMP mediated pathways for the development of IDH.  
4. Conclusions 
Intradialytic hypotension continues to be a significant challenge. Despite multiple therapies, 
no single agent or modality has been proven universally effective in the management of 
IDH. For patients who are refractory to traditional therapies (fluid infusions, vasopressor 
administration, modification of ultrafiltration rates) adjunctive treatments may hold 
promise. One of those approaches is the use of methylene blue, an inhibitor of guanylyl 
cyclase in vascular smooth muscle, as well as nitric oxide synthesis inhibitor and scavenger. 
Although early research in this promising area is encouraging, further investigation is 
needed before more widespread implementation of this therapy is undertaken. 
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